EUCTR2017-004527-67-LV进行中（未招募）1 期
A Randomised Dose Finding Study Comparing The Safety And Efficacy Of three blinded doses of Diperoxochloric Acid (DPOCl, DermaPro®) and A Standard Moist Wound Dressing In Patients With Non-Healing Diabetic Foot Ulcers - DermaPro® versus standard moist wound dressing in patients with diabetic foot ulcers
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.The patient must have given written informed consent.
- •2.Age: = 18 years, inclusive of the date of randomization.
- •3.Diabetic foot ulcer with mean diameter between 1.5 and 4 cm after débridement (1.5 and 4 cm if debridement is not indicated), determined as longest length + longest width)/2.
- •Wound shapes other than circular must have both a length and width of at least 1.5 cm;
- •Wound stage Wagner grade I or II, Armstrong stadium A or C treated unsuccessfully for at least 4weeks.
- •Should more than one eligible wound be present, only one will be selected (target wound”)
- •Note: Other wounds with impaired healing, e.g. decubitus ulcer, arterial and/or venous leg ulcer, Charcot's foot or malum perforans, may be present in the same patient but shall not be selected as targets for the present study.
- •4.Type 1 or type 2 Diabetes Mellitus under metabolic control as confirmed by a glycosylated hemoglobin (HbA1c) = 12% at screening
- •The laboratory results may not be older than 3 month at the date of randomization.
- •5.Adequate perfusion of the lower leg on the affected extremity determined by an ankle/ brachial ratio of >0.7 or systolic blood pressure of either > 50 mm Hg (big toe) or > 70 mm Hg (dorsalis pedis) as determined by an appropriate method, according to local use, concerning the foot pulse to exclude patients who require a revascularization therapy; examination results should be not older than 3 months
- •6.Females of non-childbearing potential defined as being amenorrhoeic for longer than 2 years with an appropriate clinical profile or surgically sterile.
- •If of childbearing potential the patient must use an adequate birth control and must have a negative pregnancy test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •1.Local antibiotic therapy of the target wound selected for the study.
- •2.Suspicion of bone infection or osteomyelitis* affecting the area of target wound.
- •3.Peripheral arterial occlusive disease in the pelvic region or lower. Note: The ulcer is primarily ischemic in etiology as diagnosed by an ABI of = 0.7 on the affected extremity extremities or systolic pressure of = 50 mmHg (great toe) or = 70 mmHg (dorsalis pedis).
- •4.Vascular reconstruction or angioplasty less than 3 months ago or planned revascularization procedure.
- •5.Start or change of a new off-loading strategy (already existing off-loading device at the investigator´s discretion, is optimally applied and must be maintained)
- •6.Clinically significant abnormal values in clinical chemistry except those typical for the underlying diseases mentioned in the inclusion (for ranges see laboratory manuals of the laboratories of the participating sites/ countries). These exceptions are at the discretion of the Investigator and taken into account the tolerated ranges given in Section 11.3.8.
- •Note: Patients with a high blood glucose level are eligible, provided HbAc1 =12% at screening
- •7.Severe or uncontrolled heart disease (NYHA class III or IV, see Appendix 2).
- •8.Renal failure or treatment with dialysis.
- •9.Active severe hepatic disease, which might have an impact on wound healing.
- •10.Concurrent illness or a condition that may interfere with wound healing other than those mentioned in the inclusion criteria (e. g. carcinoma, hematological disease, vasculitis, connective tissue disease, alcohol neuropathy).
- •11.Previous radiation of the region of the target wound selected for the study.
- •12.Exposure to any systemic immunosuppressive or cytostatic therapy during the previous 30 days prior to the study, including the day Informed Consent is given.
- •13.Severe psychiatric or neurological disorder.
- •14.Incapability of giving informed consent .
- •15.Co-worker, student, relative or spouse of the investigator.
- •16.Previous participation in this present study.
- •17.Participation in another experimental clinical study during the previous 3 months prior to entry into the present study.
- •18.Current drug or alcohol abuse.
- •19.Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patients at risk because of participation in the trial, or may influence the result of the trial, or the patient’s ability to participate in the trial.
研究者
相似试验
进行中（未招募）
1 期
A study to test the efficacy of a new wound healing solution (DermaPro®)in patients with diabetic foot ulcersDiabetic foot ulcer with mean diameter between 1.5 and 4 cm after débridement if indicated), Wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), treated unsuccessfully for at least 4weeks.EUCTR2017-004527-67-EEDermaTools Biotech GmbH200
尚未招募
不适用
A clinical study with random allocation of young cancer patients having fever with low neutrophil blood count for comparing the safety and cost-effectiveness of early stoppage of antibiotic without neutrophil count recovery versus with neutrophil count recovery in these patientsCTRI/2016/02/006618Dr Brijesh Arora100
招募中
4 期
Efficacy and Safety of Cryoballoon and Radiofrequency Catheter Ablation of Persistent Atrial Fibrillatioatrial fibrillation, catheter ablation, radiofrequency, cryoballoonD001281persistent atrial fibrillationJPRN-jRCT1052210003Kusano Kengo500
进行中（未招募）
1 期
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson's with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-002233-37-ITImpax Laboratories, LLC510
进行中（未招募）
1 期
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-002233-37-DEImpax Laboratories, LLC510